Status:
RECRUITING
CAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock
Lead Sponsor:
Ottawa Heart Institute Research Corporation
Conditions:
Shock, Cardiogenic
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The investigators are interested in determining if there is a meaningful benefit from the use of medications purported to increase the pumping function of the heart (i.e. inotropes) among critically i...
Detailed Description
Cardiogenic shock (CS) is a state of inadequate end-organ perfusion due to cardiac dysfunction. Acute myocardial infarction (AMI) remains the most prevalent cause of CS, with mortality reaching upward...
Eligibility Criteria
Inclusion
- Adult patients ≥ 18 years of age admitted to an intensive care unit
- SCAI class C or D cardiogenic shock
Exclusion
- Unwilling or unable to obtain informed consent by the participant or substitute decision maker
- Patients who are currently pregnant or breast-feeding
- Patients presenting with an out-of-hospital cardiac arrest (OHCA)
- Administration of milrinone or dobutamine in the 24 hours preceding anticipated randomization
- Severe obstructive valvular lesions, including aortic stenosis and/or mitral stenosis
- Dynamic left ventricular outflow tract obstruction
Key Trial Info
Start Date :
March 5 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2026
Estimated Enrollment :
346 Patients enrolled
Trial Details
Trial ID
NCT05267886
Start Date
March 5 2022
End Date
December 1 2026
Last Update
April 10 2025
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic
Rochester, Minnesota, United States, 55905
2
Hamilton Health Sciences
Hamilton, Ontario, Canada, L8L 2X2
3
University of Ottawa Heart Institute
Ottawa, Ontario, Canada, K1Y4W7